Engineering best-in-class
CAR T-cell therapy to overcome
resistance to cancer treatment

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

Our solution involves engineering CAR T-cells with enhanced genetic material and then transporting this therapeutic “cargo” into a patient’s body, so it can recognize and kill cancer cells.

Our proprietary approach to CAR T-cell therapy has the potential to eradicate certain tumor types, including advanced blood cancers, or to keep the cancer at bay for longer than is typically observed with chemotherapy or first-generation CAR T-cell therapy.

Our lead program is addressing a primary mechanism of resistance and relapse to currently available CAR T-cell therapies and is currently being evaluated in an ongoing Phase 1 clinical trial in patients with large B-cell lymphoma (LBCL). We are also leveraging our platform technologies to enable the development of additional multi-specific and multi-functional cancer pipeline programs.

We believe in our ability to, in a beautifully simple way, incorporate complex therapeutic CARGO into our CARs, with the potential to achieve durable responses that may be curative for more patients.